Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death

Mary C. Clark, Mabel Pang, Daniel K. Hsu, Fu-Tong Liu, Sven De Vos, Randy D. Gascoyne, Jonathan Said, Linda G. Baum

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy. Galectin-3 (gal-3), the only antiapoptotic member of the galectin family, is over-expressed in DLBCL. While gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the cell surface in a carbohydrate-dependent manner. The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane tyrosine phosphatase CD45. Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents. Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activity, while addition of exogenous gal-3 reduced phosphatase activity. Moreover, the increased susceptibility of DLBCL cells to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity. Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling. These data identify a novel role for cellsurface gal-3 and CD45 in DLBCL survival and suggest novel therapeutic targets to sensitize DLBCL cells to death.

Original languageEnglish (US)
Pages (from-to)4635-4644
Number of pages10
JournalBlood
Volume120
Issue number23
DOIs
StatePublished - Nov 29 2012

Fingerprint

Galectin 3
Lymphoma, Large B-Cell, Diffuse
Cell death
Cell Death
Cells
Phosphoric Monoester Hydrolases
Tyrosine
Galectins
Glycosylation
Glycosyltransferases
Non-Hodgkin's Lymphoma
Polysaccharides
Cell Survival
B-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Clark, M. C., Pang, M., Hsu, D. K., Liu, F-T., De Vos, S., Gascoyne, R. D., ... Baum, L. G. (2012). Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood, 120(23), 4635-4644. https://doi.org/10.1182/blood-2012-06-438234

Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. / Clark, Mary C.; Pang, Mabel; Hsu, Daniel K.; Liu, Fu-Tong; De Vos, Sven; Gascoyne, Randy D.; Said, Jonathan; Baum, Linda G.

In: Blood, Vol. 120, No. 23, 29.11.2012, p. 4635-4644.

Research output: Contribution to journalArticle

Clark, MC, Pang, M, Hsu, DK, Liu, F-T, De Vos, S, Gascoyne, RD, Said, J & Baum, LG 2012, 'Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death', Blood, vol. 120, no. 23, pp. 4635-4644. https://doi.org/10.1182/blood-2012-06-438234
Clark, Mary C. ; Pang, Mabel ; Hsu, Daniel K. ; Liu, Fu-Tong ; De Vos, Sven ; Gascoyne, Randy D. ; Said, Jonathan ; Baum, Linda G. / Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. In: Blood. 2012 ; Vol. 120, No. 23. pp. 4635-4644.
@article{5a06e70f546a4e3aabd2bdd84cdeb0c6,
title = "Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy. Galectin-3 (gal-3), the only antiapoptotic member of the galectin family, is over-expressed in DLBCL. While gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the cell surface in a carbohydrate-dependent manner. The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane tyrosine phosphatase CD45. Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents. Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activity, while addition of exogenous gal-3 reduced phosphatase activity. Moreover, the increased susceptibility of DLBCL cells to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity. Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling. These data identify a novel role for cellsurface gal-3 and CD45 in DLBCL survival and suggest novel therapeutic targets to sensitize DLBCL cells to death.",
author = "Clark, {Mary C.} and Mabel Pang and Hsu, {Daniel K.} and Fu-Tong Liu and {De Vos}, Sven and Gascoyne, {Randy D.} and Jonathan Said and Baum, {Linda G.}",
year = "2012",
month = "11",
day = "29",
doi = "10.1182/blood-2012-06-438234",
language = "English (US)",
volume = "120",
pages = "4635--4644",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death

AU - Clark, Mary C.

AU - Pang, Mabel

AU - Hsu, Daniel K.

AU - Liu, Fu-Tong

AU - De Vos, Sven

AU - Gascoyne, Randy D.

AU - Said, Jonathan

AU - Baum, Linda G.

PY - 2012/11/29

Y1 - 2012/11/29

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy. Galectin-3 (gal-3), the only antiapoptotic member of the galectin family, is over-expressed in DLBCL. While gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the cell surface in a carbohydrate-dependent manner. The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane tyrosine phosphatase CD45. Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents. Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activity, while addition of exogenous gal-3 reduced phosphatase activity. Moreover, the increased susceptibility of DLBCL cells to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity. Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling. These data identify a novel role for cellsurface gal-3 and CD45 in DLBCL survival and suggest novel therapeutic targets to sensitize DLBCL cells to death.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy. Galectin-3 (gal-3), the only antiapoptotic member of the galectin family, is over-expressed in DLBCL. While gal-3 can localize to intracellular sites, gal-3 is secreted by DLBCL cells and binds back to the cell surface in a carbohydrate-dependent manner. The major counterreceptor for gal-3 on DLBCL cells was identified as the transmembrane tyrosine phosphatase CD45. Removal of cell-surface gal-3 from CD45 with the polyvalent glycan inhibitor GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents. Binding of gal-3 to CD45 modulated tyrosine phosphatase activity; removal of endogenous cell-surface gal-3 from CD45 with GCS-100 increased phosphatase activity, while addition of exogenous gal-3 reduced phosphatase activity. Moreover, the increased susceptibility of DLBCL cells to chemotherapeutic agents after removal of gal-3 by GCS-100 required CD45 phosphatase activity. Gal-3 binding to a subset of highly glycosylated CD45 glycoforms was regulated by the C2GnT-1 glycosyltransferase, indicating that specific glycosylation of CD45 is important for regulation of gal-3-mediated signaling. These data identify a novel role for cellsurface gal-3 and CD45 in DLBCL survival and suggest novel therapeutic targets to sensitize DLBCL cells to death.

UR - http://www.scopus.com/inward/record.url?scp=84870521155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870521155&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-06-438234

DO - 10.1182/blood-2012-06-438234

M3 - Article

C2 - 23065155

AN - SCOPUS:84870521155

VL - 120

SP - 4635

EP - 4644

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -